» Articles » PMID: 36496334

Biopsychosocial Analysis of Antibiotic Use for the Prevention or Management of COVID-19 Infections: A Scoping Review

Overview
Publisher Elsevier
Specialty Pharmacy
Date 2022 Dec 10
PMID 36496334
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The novelty and complexity of the COVID-19 pandemic has resulted in various coping mechanisms adopted by individuals as a means of averting the perceived fatalities of the pandemic. The use of antibiotics in the management of COVID-19 is clinically recommended under specific conditions. However, there are increasing trends of non-adherence to the recommended criteria resulting in the unwarranted use of antibiotics as an adaptative approach to the ongoing pandemic.

Objective: The objective was to identify and classify factors associated with the unwarranted use of antibiotics in the management of COVID-19 from published literature and the perspectives of key stakeholders along a Biopsychosocial model.

Methods: Literature was searched in the following databases: PubMed/MEDLINE, Scopus, Embase and Google Scholar for studies published between 31 December 2019 and 31 January 2022. The Arskey and O'Malley framework modified by Levac in the six-stage methodological process was adopted for this review and included: a) identification of research questions, b) identification of relevant research articles, c) selection of studies, d) data charting and synthesis, e) summary, discussion and analysis, and f) stakeholder consultations.

Results: Out of 10,252 records identified from all sources, 12 studies were selected for inclusion in this scoping review. The selected articles reflected both antibiotic use and COVID-19 whilst capturing the biological (medical) and psychosocial perspectives. Most of the studies reported the overuse or abuse of Azithromycin especially in hospital settings. Common themes across the review and stakeholder consultations included fear, anxiety, media influences and deficits in public knowledge.

Conclusion: The findings of the study highlight the complexity of antibiotic control especially in the context of a pandemic. The identified determinants of antibiotic use provide the necessary framework to simulate health emergencies and be better positioned in the future through the development of targeted and comprehensive policies on antibiotic stewardship.

Citing Articles

Exploring the Influence of Family Attitudes and Individual Psychological Factors on Antibiotic Utilization: A Pilot Study.

Castellano P, Russo P, Mazzetti M Healthcare (Basel). 2024; 12(12).

PMID: 38921327 PMC: 11202973. DOI: 10.3390/healthcare12121213.


Use of antimicrobials during the COVID-19 pandemic: A qualitative study among stakeholders in Nepal.

Dhungel B, Thapa Shrestha U, Adhikari S, Adhikari N, Bhattarai A, Pokharel S PLOS Glob Public Health. 2023; 3(11):e0002166.

PMID: 37963156 PMC: 10645294. DOI: 10.1371/journal.pgph.0002166.


Gaps and barriers in the implementation and functioning of antimicrobial stewardship programmes: results from an educational and behavioural mixed-methods needs assessment in France, the United States, Mexico and India-authors' response.

Lazure P, Augustyniak M, Goff D, Villegas M, Apisarnthanarak A, Peloquin S JAC Antimicrob Resist. 2023; 5(4):dlad082.

PMID: 37448707 PMC: 10336296. DOI: 10.1093/jacamr/dlad082.


Biopsychosocial analysis of antibiotic use for the prevention or management of COVID-19 infections: A scoping review.

Nortey R, Kretchy I, Koduah A, Buabeng K Res Social Adm Pharm. 2022; 19(4):573-581.

PMID: 36496334 PMC: 9715464. DOI: 10.1016/j.sapharm.2022.11.011.

References
1.
Wegbom A, Edet C, Raimi O, Fagbamigbe A, Kiri V . Self-Medication Practices and Associated Factors in the Prevention and/or Treatment of COVID-19 Virus: A Population-Based Survey in Nigeria. Front Public Health. 2021; 9:606801. PMC: 8213209. DOI: 10.3389/fpubh.2021.606801. View

2.
Min J, Jang Y . Macrolide therapy in respiratory viral infections. Mediators Inflamm. 2012; 2012:649570. PMC: 3375106. DOI: 10.1155/2012/649570. View

3.
Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement. Open Med. 2011; 3(3):e123-30. PMC: 3090117. View

4.
Blanco C, Compton W, Volkow N . Opportunities for Research on the Treatment of Substance Use Disorders in the Context of COVID-19. JAMA Psychiatry. 2020; . DOI: 10.1001/jamapsychiatry.2020.3177. View

5.
Buckner J, Heimberg R, Ecker A, Vinci C . A biopsychosocial model of social anxiety and substance use. Depress Anxiety. 2012; 30(3):276-84. DOI: 10.1002/da.22032. View